What target does Sotorasib target?

Sotorasib targets a specific mutation in the RAS protein, specifically the G12C G12C mutation in the KRAS gene. RASProteins are a type of protein that play a key role in cell signaling pathways, regulating key biological processes such as cell growth, division and survival. KRAS is a subtype of the RAS family and is often associated with the occurrence and development of various cancers.

Under normal circumstances, RAS protein transmits growth signals within cells and helps maintain normal cell biological functions. However, when the RAS protein is mutated, particularly the G12C mutation in the KRAS gene, it can lead to abnormally active RAS proteins, triggering uncontrolled growth of cells and thus promoting the development of cancer.

Sotorasiib targets this KRAS G12C mutation, which blocks abnormal growth signaling pathways in cancer cells by specifically binding to and inhibiting the activity of KRAS G12C mutant protein. This mutation-specific targeted therapy is an innovative approach that promises to provide a new treatment option for cancer patients with the KRAS G12C mutation.

The development and application of sotoracib represents a major advance in the field of cancer treatment, because treatingRAS gene mutations has long been considered a huge challenge. By targeting a therapeutic strategy specifically targeting the KRAS G12C mutation, sotoraxib provides the medical community with a breakthrough approach and new hope for those living with this mutation. With further research and clinical practice, this treatment strategy is expected to become an important milestone in the field of future cancer treatment.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. Specifications of sotorasibu, original research version from Hong Kong, China120mg*240The price of tablets is around 8 million, while the European version of the original drug with the same specification is priced around 4 million, which is more expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.